Application of mass spectrometry profiling to establish brusatol as an inhibitor of global protein synthesis

Molecular and Cellular Proteomics

Volumn 15, Issue 4, 2016, Pages 1220-1231

  Steffan, Vartanian ^a   Taylur, P ^a   James, Lee ^a   Peter, M Haverty ^b   Donald, S Kirkpatrick ^a   Yu, Kebing ^a   Stokoe, David ^a  

^a Department of Discovery Oncology ^*  (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUSATOL; CYCLOHEXIMIDE; CYSTATIN C; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MESSENGER RNA; NRCAM PROTEIN; PLANT MEDICINAL PRODUCT; PROTEIN; PROTEOME; SILVESTROL; SMALL INTERFERING RNA; THROMBOCYTE ACTIVATING FACTOR; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; KEAP1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; PROTEIN SYNTHESIS INHIBITOR; QUASSINOID DERIVATIVE;

A549 CELL LINE; ARTICLE; BIOTINYLATION; CELL LYSATE; CELL MEDIATED CYTOTOXICITY; COMPARATIVE STUDY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MELTING POINT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TEMPERATURE SENSITIVITY; THERMOSTABILITY; UPREGULATION; WESTERN BLOTTING; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION; PROCEDURES; PROTEOMICS; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; LUNG NEOPLASMS; MASS SPECTROMETRY; MUTATION; NF-E2-RELATED FACTOR 2; PROTEIN SYNTHESIS INHIBITORS; PROTEOMICS; QUASSINS;

EID: 84994612331     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M115.055509     Document Type: Article

References (42)

1. Rachakonda, G., Xiong, Y., Sekhar, K. R., Stamer, S. L., Liebler, D. C., and Freeman, M. L. (2008) Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3. Chem. Res. Toxicol. 21, 705-710
2. Tong, K. I., Kobayashi, A., Katsuoka, F., and Yamamoto, M. (2006) Two-site substrate recognition model for the Keap1-Nrf2 system: A hinge and latch mechanism. Biol. Chem. 387, 1311-1320
3. Nishizawa, M., Kataoka, K., Goto, N., Fujiwara, K. T., and Kawai, S. (1989) v-maf, a viral oncogene that encodes a "leucine zipper" motif. Proc. Natl. Acad. Sci. U.S.A. 86, 7711-7715
4. Malhotra, D., Portales-Casamar, E., Singh, A., Srivastava, S., Arenillas, D., Happel, C., Shyr, C., Wakabayashi, N., Kensler, T. W., Wasserman, W. W., and Biswal, S. (2010) Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 38, 5718-5734
5. Chorley, B. N., Campbell, M. R., Wang, X., Karaca, M., Sambandan, D., Bangura, F., Xue, P., Pi, J., Kleeberger, S. R., and Bell, D. A. (2012)Identification of novel NRF2-regulated genes by ChIP-Seq: Influence on retinoid X receptor alpha. Nucleic Acids Res. 40, 7416-7429
6. Hirotsu, Y., Katsuoka, F., Funayama, R., Nagashima, T., Nishida, Y., Nakayama, K., Engel, J. D., and Yamamoto, M. (2012) Nrf2-MafG heterodimers contribute globally to antioxidant and metabolic networks. Nucleic Acids Res. 40, 10228-10239
7. Cancer Genome Atlas Research, N. (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550
8. Cancer Genome Atlas Research, N. (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525
9. Hast, B. E., Cloer, E. W., Goldfarb, D., Li, H., Siesser, P. F., Yan, F., Walter, V., Zheng, N., Hayes, D. N., and Major, M. B. (2014) Cancer-derived mutations in KEAP1 impair NRF2 degradation but not ubiquitination. Cancer Res. 74, 808-817
10. Singh, A., Boldin-Adamsky, S., Thimmulappa, R. K., Rath, S. K., Ashush, H., Coulter, J., Blackford, A., Goodman, S. N., Bunz, F., Watson, W. H., Gabrielson, E., Feinstein, E., and Biswal, S. (2008) RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 68, 7975-7984
11. Ren, D., Villeneuve, N. F., Jiang, T., Wu, T., Lau, A., Toppin, H. A., and Zhang, D. D. (2011) Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl. Acad. Sci. U.S.A. 108, 1433-1438
12. Olayanju, A., Copple, I. M., Bryan, H. K., Edge, G. T., Sison, R. L., Wong, M. W., Lai, Z. Q., Lin, Z. X., Dunn, K., Sanderson, C. M., Alghanem, A. F., Cross, M. J., Ellis, E. C., Ingelman-Sundberg, M., Malik, H. Z., Kitteringham, N. R., Goldring, C. E., and Kevin Park, B. (2014) Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2. Free Radical Biol. Med. 78, 202-212
13. Martinez Molina, D., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., and Nordlund, P. (2013) Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84-87
14. Savitski, M. M., Reinhard, F. B., Franken, H., Werner, T., Savitski, M. F., Eberhard, D., Martinez Molina, D., Jafari, R., Dovega, R. B., Klaeger, S., Kuster, B., Nordlund, P., Bantscheff, M., and Drewes, G. (2014) Proteomics. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 346, 1255784
15. Yang, Z., Xie, H., and Wang, J. (1996) Chemical studies of the active antitumor components from the fruits of Brucea javanica. Natural Product Research and Development 1996, 35-39
16. Sim, K. Y., Sims, J. J., and Geissman, T. A. (1968) Constituents of Brucea sumatrana J. Organic Chem. 33, 429-431
17. Beausoleil, S. A., Villén, J., Gerber, S. A., Rush, J., and Gygi, S. P. (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat. Biotechnol. 24, 1285-1292
18. Meerbrey, K. L., Hu, G., Kessler, J. D., Roarty, K., Li, M. Z., Fang, J. E., Herschkowitz, J. I., Burrows, A. E., Ciccia, A., Sun, T., Schmitt, E. M., Bernardi, R. J., Fu, X., Bland, C. S., Cooper, T. A., Schiff, R., Rosen, J. M., Westbrook, T. F., and Elledge, S. J. (2011) The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 108, 3665-3670
19. Friedman, J., Hastie, T., and Tibshirani, R. (2010) Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1-22
20. Kuhn, M., Wing, J., Weston, S., Williams, A., Keefer, K., Engelhardt, A., Cooper, T., Mayer, Z., Kenkel, B., Benesty, M., Lescarbeau, R., Ziem, A., Scrucca, L., Tang, Y., and Candan, C. (2015) caret: Classification and regression training. R package version 6.0-58
21. Jafari, R., Almqvist, H., Axelsson, H., Ignatushchenko, M., Lundbäck, T., Nordlund, P., and Martinez Molina, D. (2014) The cellular thermal shift assay for evaluating drug target interactions in cells. Nat. Protoc. 9, 2100-2122
22. Bloom, J., Amador, V., Bartolini, F., DeMartino, G., and Pagano, M. (2003)Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell 115, 71-82
23. Choudhary, G. S., Tat, T. T., Misra, S., Hill, B. T., Smith, M. R., Almasan, A., and Mazumder, S. (2015) Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics. Oncotarget 6, 16912-16925
24. Larance, M., Ahmad, Y., Kirkwood, K. J., Ly, T., and Lamond, A. I. (2013)Global subcellular characterization of protein degradation using quantitative proteomics. Mol. Cell. Proteomics 12, 638-650
25. Song, W., Wang, Y., Yu, Z., Vera, C. I., Qu, J., and Lin, Q. (2010) A metabolic alkene reporter for spatiotemporally controlled imaging of newly synthesized proteins in Mammalian cells. ACS Chem. Biol. 5, 875-885
26. Lindqvist, L., and Pelletier, J. (2009) Inhibitors of translation initiation as cancer therapeutics. Future Medicinal Chem. 1, 1709-1722
27. Ramos-Gomez, M., Kwak, M. K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., and Kensler, T. W. (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 98, 3410-3415
28. Xu, C., Huang, M. T., Shen, G., Yuan, X., Lin, W., Khor, T. O., Conney, A. H., and Kong, A. N. (2006) Inhibition of 7,12-dimethylbenz(a)anthraceneinduced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res. 66, 8293- 8296
29. Cheung, K. L., Lee, J. H., Khor, T. O., Wu, T. Y., Li, G. X., Chan, J., Yang, C. S., and Kong, A. N. (2014) Nrf2 knockout enhances intestinal tumorigenesis in Apc(min/) mice due to attenuation of anti-oxidative stress pathway while potentiates inflammation. Mol. Carcinog. 53, 77- 84
30. Magesh, S., Chen, Y., and Hu, L. (2012) Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med. Res. Rev. 32, 687-726
31. Zhang, D. D., and Hannink, M. (2003) Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol. Cell. Biol. 23, 8137-8151
32. Jiang, Z. Y., Lu, M. C., Xu, L. L., Yang, T. T., Xi, M. Y., Xu, X. L., Guo, X. K., Zhang, X. J., You, Q. D., and Sun, H. P. (2014) Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis. J. Med. Chem. 57, 2736-2745
33. Hu, L., Magesh, S., Chen, L., Wang, L., Lewis, T. A., Chen, Y., Khodier, C., Inoyama, D., Beamer, L. J., Emge, T. J., Shen, J., Kerrigan, J. E., Kong, A. N., Dandapani, S., Palmer, M., Schreiber, S. L., and Munoz, B. (2013)Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction. Bioorg. Med. Chem. Lett. 23, 3039-3043
34. Leinonen, H. M., Kansanen, E., Pölönen, P., Heinaniemi, M., and Levonen,A. L. (2014) Role of the keap1-nrf2 pathway in cancer. Adv. Cancer Res. 122, 281-320
35. Tarumoto, T., Nagai, T., Ohmine, K., Miyoshi, T., Nakamura, M., Kondo, T., Mitsugi, K., Nakano, S., Muroi, K., Komatsu, N., and Ozawa, K. (2004)Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line. Exp. Hematol. 32, 375-381
36. Tang, X., Wang, H., Fan, L., Wu, X., Xin, A., Ren, H., and Wang, X. J. (2011)Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radical Biol. Med. 50, 1599-1609
37. Wang, X. J., Hayes, J. D., Henderson, C. J., and Wolf, C. R. (2007)Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc. Natl. Acad. Sci. U.S.A. 104, 19589-19594
38. Tao, S., Wang, S., Moghaddam, S. J., Ooi, A., Chapman, E., Wong, P. K., and Zhang, D. D. (2014) Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer Res. 74, 7430-7441
39. Willingham, W., Jr., Stafford, E. A., Reynolds, S. H., Chaney, S. G., Lee, K. H., Okano, M., and Hall, I. H. (1981) Mechanism of eukaryotic protein synthesis inhibition by brusatol. Biochim. Biophys. Acta 654, 169-174
40. Liou, Y. F., Hall, I. H., Okano, M., Lee, K. H., and Chaney, S. G. (1982)Antitumor agents XLVIII: Structure-activity relationships of quassinoids as in vitro protein synthesis inhibitors of P-388 lymphocytic leukemia tumor cell metabolism. J. Pharma. Sci. 71, 430-435
41. Tan, B. X., Brown, C. J., Ferrer, F. J., Yuen, T. Y., Quah, S. T., Chan, B. H., Jansson, A. E., Teo, H. L., Nordlund, P., and Lane, D. P. (2015) Assessing the efficacy of Mdm2/Mdm4-inhibiting stapled peptides using cellular thermal shift assays. Sci. Reports 5, 12116
42. Griffith, J. P., Kim, J. L., Kim, E. E., Sintchak, M. D., Thomson, J. A., Fitzgibbon, M. J., Fleming, M. A., Caron, P. R., Hsiao, K., and Navia, M. A. (1995) X-ray structure of calcineurin inhibited by the immunophilinimmunosuppressant FKBP12-FK506 complex. Cell 82, 507-522